5.87

1.43% -0.085

Eupraxia Pharmaceuticals Inc (EPRX)

Overview News Price History Discussions Forecast

Eupraxia Pharmaceuticals Inc stock is traded at $5.87, with a volume of 81,853. It is down -1.43% in the last 24 hours and up +7.71% over the past month. Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Previous Close:

$5.955

Open:

$6.01

24h Volume:

81,853

Relative Volume:

0.74

Market Cap:

$297.31M

Revenue:

Net Income/Loss:

$-25.50M

P/E Ratio:

-7.6234

EPS:

-0.77

Net Cash Flow:

$-30.10M

1W Performance:

-5.78%

1M Performance:

+7.71%

6M Performance:

+47.86%

1Y Performance:

+86.35%

1-Day Range:

$5.85

$6.01

1-Week Range:

$5.72

$6.44

52-Week Range:

$2.6801

$7.19

Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile

Name

Eupraxia Pharmaceuticals Inc

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

Address

Employee

Twitter

Next Earnings Date

2025-08-08

Latest SEC Filings

EPRX's Discussions on Twitter

Compare EPRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EPRX Eupraxia Pharmaceuticals Inc	5.87	301.61M	0	-25.50M	-30.10M	-0.77
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-25	Initiated	Cantor Fitzgerald	Overweight
Jun-26-25	Initiated	H.C. Wainwright	Buy
Jun-16-25	Initiated	Canaccord Genuity	Speculative Buy
Feb-21-25	Initiated	Craig Hallum	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy

Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News

01:55 AM

Will Eupraxia Pharmaceuticals Inc. (X43) stock outperform global peersJuly 2025 Setups & Consistent Growth Equity Picks - Newser

01:55 AM

Dec 04, 2025

Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why - Finviz

Dec 04, 2025

Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here’s Why - Yahoo Finance

Dec 04, 2025

(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com

Dec 04, 2025

Net current asset value per share of Eupraxia Pharmaceuticals, Inc. – LS:A3EGRS - TradingView

Dec 04, 2025

Is Eupraxia Pharmaceuticals Inc. stock a bargain at current levelsWeekly Trade Review & Long-Term Safe Investment Plans - Newser

Dec 04, 2025

Is Eupraxia Pharmaceuticals Inc. (X43) stock testing key supportJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser

Dec 04, 2025

How Eupraxia Pharmaceuticals Inc. (X43) stock correlates with oil markets2025 Institutional Moves & Weekly High Potential Alerts - Newser

Dec 04, 2025

Is Eupraxia Pharmaceuticals Inc. stock oversold or undervaluedRate Hike & Fast Entry Momentum Trade Alerts - Newser

Dec 04, 2025

How forex fluctuations impact Eupraxia Pharmaceuticals Inc. (X43) stockPortfolio Performance Report & Stock Market Timing Techniques - Newser

Dec 04, 2025

Dec 03, 2025

Is Eupraxia Pharmaceuticals Inc. (X43) stock expanding market penetration2025 Key Lessons & Low Risk High Win Rate Picks - Newser

Dec 03, 2025

(EPRX) Investment Analysis and Advice (EPRX:CA) - news.stocktradersdaily.com

Dec 03, 2025

Dec 02, 2025